Linda Burkly
Known title: EVP, CHIEF SCIENTIFIC OFFICERCIK: 0001985604
Associated companies
Transaction History
| EDIT | ▼ Sell | Open Market | 709 | $2K | 9/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 4,928 | $13K | 7/28/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 731 | $2K | 6/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 749 | $2K | 3/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 713 | $2K | 12/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 710 | $2K | 9/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 5,121 | $13K | 7/31/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 726 | $1K | 6/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 2,891 | $5K | 3/4/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 11,886 | $64K | 7/25/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 15,055 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 24,800 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 45,167 | $0 | 7/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.